Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arlocabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
NCT06297226Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2024
- Primary completion
- Jul 2026
- Modality
- CAR-T Cells
- Countries
- 4
01
Overview
Phase 2, open-label trial of arlocabtagene autoleucel in multiple myeloma (MM) (2 cohorts), sponsored by Bristol Myers Squibb. Primary endpoint: Best Overall Response of Partial Response or Better. Started Mar 2024; status: recruiting.
02
Drugs
arlocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06297226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06297226.